Investigational drug · Phase 2
FB 301
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bacterial Vaginosis (BV), Vaginal Dysbiosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "FB 301"
First trial start
2026
Mar 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FB 301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bacterial Vaginosis (BV)
- Vaginal Dysbiosis
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "FB 301" as an intervention, largest first.
- Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment TrialPivotal-lookingRecruiting
Freya Biosciences ApSIndustry
NCT07481955 · 120 participants (planned) · Start Mar 23, 2026 · Primary completion Mar 3, 2027
Drug: FB 301; Chlorhexidine 0.5% and 1 more · For: Bacterial Vaginosis (BV)
Sites: Berlin, Germany; Mannheim, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.